It Coconut Oil for Pets another object Rexveratrol the invention to Resvratrol such a method wherein Coconut Oil for Pets formulation is administered orally. Pharmacol Healhh. The data Muscle recovery and growth and discussed here indicate that the reported resveratrol benefits are not only disease-preventive but also disease-ameliorative; thus, it would not be surprising if this nutraceutical becomes more adopted into the routine management of PF patients or those at high risks of similar fibrotic diseases. Toxicol Sci.

Video

Chew a Pinch of This roomroom.info Stomach, Heart, Arteries, BP and Lungs Will Love You! Dr. Mandell US scientists Balancing water retention demonstrated that resveratrol administered via the lung may respiatory promise in slowing down lung structure damage and Coconut Oil for Pets in respirafory. The team noticed that resveratrol targeted the cell lining of the hdalth Resveratrol and respiratory health the mechanism exchange Resliratory oxygen and carbon dioxide. Primarily found in grapes and red wine, the nutrient can also be found in walnuts, peanuts and berries. This is not the first time that the polyphenol had been looked at within a healthy ageing capacity. Using a mouse model that aged quicker than normal the team looked at whether the build-up of damage as the animals aged could be halted by inhaled resveratrol. A month after the procedure had ended, lung function, structure and cellular DNA damage were assessed.

Resveratrol and respiratory health -

The cell lining of the lungs known as alveolar epithelial type 2 cells AEC2 , which play a major role in gas exchange, were also assessed. The researchers found that resveratrol treatments delayed the loss of lung function, maintained lung structure and appeared to block cell DNA damage.

They added that resveratrol given directly to the lungs may be an effective intervention for age-related lung decline, which is classed as a risk factor for chronic lung disease development. The mechanism of this action may be explained by the resveratrol controlled Sirtuin SIRT1 activity.

SIRT1 is an enzyme that disarms proteins that contribute to cellular regulation such as reaction to stressors and preserving longevity. The resveratrol—SIRT1 pathway has also been linked to an extension of the lifespan in several animals as well as improving mitochondrial function in mice.

Published online ahead of print: doi. Show more. Content provided by Valio Jan White Paper. Read our white paper to learn how to overcome taste and texture challenges in protein products — and how to commercialise the protein trend by making delicious Content provided by LEHVOSS Nutrition Jan White Paper.

When exploring the world of liposomal ingredients, finding the right one is key. Content provided by Gencor Oct Product Brochure. In a recent clinical trial backing its ingredient Libifem® for improved muscle strength, power, endurance and body composition with a females-only popluation Content provided by FoodChain ID Oct White Paper.

for 60 s] cycles followed by 10 minutes at 72° C. Specific primers for iNOS PCR gave a PCR product of bp; specific primers for GADPH PCR gave a PCR product of bp. Samples that did not contain reverse transcriptase were employed as negative controls.

Primary epithelial cells were treated for 4 hours with cytomix in the presence of resveratrol, or one of dexamethasone and budenoside, and assayed for iNOS mRNA. Only resveratrol inhibited iNOS expression as measured by mRNA.

Inhibition of Inflammatory Gene Expression and IL-8 Release by Resveratrol Compared to Steroids in Human Airway Epithelial Cells:. The EC 50 for inhibition of the release of IL-8 by these cells was determined to be ±2.

GM-CSF release was measured in culture media by sandwich assay employing rat monoclonal capture antibody Ab, mAb against GM-CSF and a biotinylated rat anti-human GM-CSF mAb.

The rat capture mAb against GM-CSF, diluted in 0. onto 96 well plates. After washing, with wash buffer NaCl: mM, KCl: 4 mM, NaH 2 PO 4 : 10 mM, Tween 0. After washing, samples and standards were added to the well plates and incubated at 4° C.

The expression of inflammatory genes was then evaluated in cells transformed with luciferase reporter genes containing sites for transcription factors Tf, Tfs. The A cells were stably transfected by routine methods with luciferase reporters containing the transcription factors NF-κB, TRE AP-1, TPA responsive element and CRE cAMP responsive element.

Resveratrol inhibited NF-κB dependent transcription completely with an EC 50 value of 21±7 μM. Oral Administration of Resveratrol for Treating Asthma:. Resveratrol is evaluated clinically for efficacy in treating asthma.

The methods of the following references are generally used in the evaluation of asthmatic disease: Wohl et al. Patients with asthma are treated once or more per day with gelatin capsules containing resveratrol. Patients are medically monitored for clinical symptoms of asthma throughout the study, including frequency and severity of acute asthma attacks.

In addition, blood serum and induced sputum samples are obtained from the patients at days 0, 30, 90, and and are assayed for IL-8 Tang et al.

Asthma 37 5 [describing use of serum IL-8 sIL-8 ] and eosinophil cationic protein ECP Baba et al. Asthma 37 5 [describing use of serum ECP sECP ] by routine methods. In addition exhaled nitric oxide NO and carbon monoxide CO levels may be measured at more frequent intervals, such as every other week.

Forced expiratory volume FEV and forced inspiratory volume FIV are also evaluated to measure airway patency as a direct measure of clinical morbidity and to determine correlation the histopathologic and other indicators of clinical disease, such as exhaled NO Immunhistopathologic examination of lung tissue biopsy samples taken at the same intervals as the blood samples are also examined for histopathologic evidence of extent and histology of inflammation.

Experimental work conducted according to the documented procedures shows that resveratrol and related compounds of this invention are effective for treating asthma. Pulmonary Administration of Resveratrol for Treating Asthma:.

Resveratrol is evaluated clinically for efficacy in treating asthma when administered pulmonarily. Med 15 Patients with asthma are treated once or more per day with inhalator delivered pulmonary administered doses of resveratrol. Comparison of Oral or Inhaled Resveratrol and Inhaled Glucocorticoids for Treating COPD in Steroid Naive Patients:.

Steroid naive patients suffering from different COPDs patients are selected and divided into populations according to the COPD. Chronic bronchitis populations and emphysema populations are appropriately studied.

The populations are divided in terms of progression of their COPD into subpopulations early or mild, mid-stage or moderate, and advanced impairment of lung function. The study is generally patterned after the asthma studies with modifications appropriate to the clinical and histopathologic evaluation of COPD disease, and the references listed in the preceding examples may be applied as appropriate.

One major difference is that the COPD study should last for 1 to 2 years or longer, because of the chronic nature of COPD. Each subpopulation is divided equally and randomly into three groups.

Patients are medically monitored for clinical symptoms of COPD throughout the study, including frequency and severity of hypoxemic and respiratiry acidotic exacerbations. In addition, blood serum and induced sputum samples are obtained from the patients at days 0, 30, 60, 90, , and every 30 days thereafter, and neutrophil counts are performed and the samples are assayed for IL-8 and myeloperoxidase activity by routine methods.

Forced expiratory volume FEV and forced inspiratory volume FIV are also evaluated to measure airway patency as a direct measure of clinical morbidity and to determine correlation the histopathologic and other indicators of clinical disease.

Immunhistopathologic examination of lung tissue biopsy samples taken at the same intervals as the blood samples are also examined for histopathologic evidence of extent and histology of inflammation. Experimental work conducted according to the documented procedures shows that pulmonary delivered and oral resveratrol and related compounds of this invention are more effective for treating COPD than inhaled steroids, and exhibit fewer systemic effects than patients treated with inhaled glucocorticosteroids.

COPD is shown to be more responsive to the therapy in earlier compared to more progressive disease. Resveratrol Substitution for Glucocorticoids vs. Initiation of Steroids in Treatment of Asthma:. Asthmatic steroid naive children with asthma disease severe enough to require chronic pulmonary steroid therapy are divided randomly and blindly into three groups.

The duration of the study should be long, as pulmonary steroids for asthma are a chronic therapy, thus 1 to 2 years or more is optimal. The methods of the following references may be used in the evaluation of asthmatic disease: Wohl et al.

Forced expiratory volume FEV and forced inspiratory volume FIV are also evaluated to measure airway patency as a direct measure of clinical morbidity and to determine correlation the histopathologic and other indicators of clinical disease, such as exhaled NO.

Experimental work conducted according to the documented procedures shows that oral and pulmonary resveratrol and related compounds of this invention are effective as substitutes for antiinflammatory treatment with inhaled steroids in treating asthma, and may be clinically substituted for inhaled glucocorticoids with equal therapeutic effect on all measured parameters and reduced systemic side effects including reduced suppression of growth upon instigation of therapy.

Evaluation of Resveratrol Supplementation for Glucocorticoids vs. Increasing Dose of Steroids in Treatment of Steroid Resistant Asthma:.

Instead of steroid naive chid asthmatic patients children are chosen because of the increased gravity of systemic endocrine effects for children, but adults can be analogously studied selected in Example 6, patients reesistant to existing pulmonary steroid therapy are selected.

The study is otherwise analogous to the study in Example 7, except that in the first two groups the oral or inhaled resveratrol supplements the inhaled steroid dose being administered prior to the beginning of the evaluation, while the third group has the dosage of inhaled steroid being administered prior to the study doubled.

Alternatively the third group can receive oral prednisone in the appropriate systemic dose. The evaluation is otherwise performed identically to that in Example 6. Experimental work conducted according to the documented procedures shows that oral and pulmonary resveratrol and related compounds of this invention are as or more effective as supplements to existing steroid therapy for antiinflammatory treatment than doubling inhaled steroid dose in treating asthma.

Resveratrol supplementation is therefore clinically preferable to increasing inhaled glucocorticoids with equal or better therapeutic effect on all measured parameters and reduced systemic side effects compared with doubling steroid dosage, including reduced suppression of growth upon instigation of increased dose.

Clinical Evaluation of Oral Resveratrol for Treating COPD:. Resveratrol is evaluated clinically for efficacy in treating COPD. Smokers are treated once or more per day with gelatin capsules containing resveratrol. The different populations of COPD patients are subdivided into subpopulations: emphysema patients, bronchitis patients and other COPD.

In addition, induced sputum samples are obtained from the patients at days 0, 30, 90, and and neutrophil counts are performed and the samples are assayed for IL-8 and myeloperoxidase by routine methods. Experimental work conducted according to the documented procedures shows that oral resveratrol and related compounds of this invention are effective for treating COPD.

Clinical Evaluation of Pulmonary Resveratrol for Chemoprevention of COPD:. Pulmonary administration of resveratrol for COPD may be evaluated by the method preceding in Example 8, using the inhaled doses specified in Example 4.

Experimental work conducted according to the documented procedures shows that pulmonary resveratrol and related compounds of this invention are effective for treating COPD. Evaluation of Oral Administration of Resveratrol for Chemoprevention of COPD in Smokers:. Resveratrol is evaluated clinically for efficacy in chemoprevention of COPD in smokers.

Smokers with no disease or mild COPD are treated once or more per day with gelatin capsules containing resveratrol. The population of smokers are subdivided into subpopulations: clinically and histopathologically disease free, clinically asymptomatic with histopathologic inflammation and mildly COPD symptomatic, meaning some chronic bronchitis but no pulmonary impairment causing hypoxemia or acidosis.

The study should be conducted as long as the patient population can be followed. Patients are medically monitored for clinical symptoms of COPD throughout the study, including onset of symptoms and frequency and severity thereof. In addition, induced sputum samples are obtained from the patients at days 0, 30, 60, 90, , and every 30 days thereafter, and neutrophil counts are performed and the samples are assayed for IL-8 and myeloperoxidase by routine methods.

Experimental work conducted according to the documented procedures shows that oral resveratrol and related compounds of this invention are effective for chemoprevention of COPD in smokers without significant side effects that would be expected from steroid administration, with the chemoprevention most effective when instituted as early as possible in the pathophysiologic process.

This study can be analogously performed for pulmonary administration of resveratrol in the doses stated in the preceding examples. Evaluation of Oral Administration of Resveratrol for Chemoprevention of ILD in Individuals at Risk:. Resveratrol is evaluated clinically for efficacy in chemoprevention of ILD in smokers.

The study is generally patterned after the COPD chemoprevention study Example 10 with modifications appropriate to the clinical and histopathologic evaluation of ILD, and the references listed in the preceding examples may be applied as appropriate.

Individuals at risk with no disease or mild COPD are treated once or more per day with gelatin capsules containing resveratrol.

A population of individuals at risk for a specific ILD, such as silicosis can be studied, or several such populations such as sand blasters silicosis and coal miners can be studied in parallel The different populations are subdivided into subpopulations: clinically and histopathologically disease free, clinically asymptomatic with histopathologic inflammation and mildly ILD symptomatic, meaning some fibrosis but no pulmonary impairment causing hypoxemia or acidosis.

Patients are medically monitored for clinical symptoms of ILD throughout the study, including onset of symptoms and frequency and severity thereof. Experimental work conducted according to the documented procedures shows that oral resveratrol and related compounds of this invention are effective for chemoprevention of ILD without significant side effects that would be expected from steroid administration, with the greatest chemopreventive effect found when the therapy is instituted as early in the histopathologic course of the disease.

A method for treating interstitial lung disease in a patient suffering from or predisposed to developing interstitial lung disease ILD , comprising administering to the patient a pharmaceutical formulation that comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of an active agent selected from the group consisting of resveratrol, pharmacologically acceptable salts, esters, amides, prodrugs or analogs thereof, and combinations thereof.

The method of claim 1 , wherein the active agent is cis-resveratrol or a pharmacologically acceptable salt, ester, amide, prodrug or analog thereof. The method of claim 2 , wherein the active agent is cis-resveratrol.

The method of claim 2 , wherein the active agent is a conjugate of cis-resveratrol and a mono- or di-saccharide. The method of claim 4 , wherein the active agent is cis-resveratrol glucoside. The method of claim 1 , wherein the active agent is trans-resveratrol or a pharmacologically acceptable salt, ester, amide, prodrug or analog thereof.

The method of claim 6 , wherein the active agent is trans-resveratrol. The method of claim 6 , wherein the active agent is a conjugate of trans-resveratrol and a mono- or di-saccharide.

The method of claim 8 , wherein the active agent is trans-resveratrol glucoside. The method of claim 1 , wherein the active agent comprises a mixture of cis-resveratrol and trans-resveratrol. The method of claim 1 , wherein the active agent is delivered orally. The method of claim 1 , wherein the active agent is delivered by pulmonary administration.

The method of claim 1 , wherein the active agent is delivered parenterally. The method of claim 13 , wherein the active agent is delivered to the alveoli. The method of claim 1 , further comprising the co-administration of an additional active agent.

The method of claim 15 , wherein the formulation further includes an additional active agent. The method of claim 16 , wherein the additional active agent is selected from the group consisting of glucocorticoids, non-steroidal antiinflammatory drugs, macrolide antibiotics, bronchodilators, leukotriene receptor inhibitors, cromolyn sulfate and combinations thereof.

The method of claim 17 , wherein the additional active agent is selected from the group consisting of phosphodiesterase inhibitors, long acting β 2 adrenergic agonists, and combinations thereof. The method of claim 18 , wherein the additional active agent is selected from the group consisting of theophylline, salmetrol xinafoate, and a combination thereof.

The method of claim 1 , wherein the ILD is fibrosing alveolitis, sarcoidiosis, or fibrotic lung disease. DET DET2 en. PTT PTE en. EPA EPB1 en. Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders.

DKT DKT3 en. ATT ATET1 en. AUA AUA1 en. CAA CAC en. EST EST3 en. ZAA ZAB en. CYT CYT1 en. USB1 true USB1 en. USB1 en. EPB1 en. ATET1 en. AUA1 en. CAC en. CYT1 en. DET2 en. DKT3 en. EST3 en. PTE en. WOA2 en. ZAB en. Methods for making pharmaceutical formulations comprising deagglomerated microparticles.

Clarithromycin or a salt thereof for the treatment or prevention of pulmonary disorders caused by the destruction of pulmonary alveoli. Combination therapy using budesonide and antisense oligonucleotide targeted to il4-receptor alpha.

Processes for making particle-based pharmaceutical formulations for oral administration. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders.

Pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system. Prolyl Endopeptidase Inhibitors For Reducing or Preventing Neutrophilic Inflammation.

Modulating the Activity of Nuclear Receptors in Order to Treat Hypoxia-Related Disorders. Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders.

Pharmaceutical and nutraceutical compositions for treating respiratory disease and associated phlegm. USB2 en. Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use.

Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms. Method for treating infectious diseases with isothiocyanate functional compounds.

Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms. Method for treating benign prostatic hyperplasia BPH , prostatitis, and prostate cancer. Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases.

EPA1 en. Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection.

Anticancer and antiprotozoal dihydroartemisinene and dihydroartemisitene dimers with desirable chemical functionalities. TWIB en. BRPIB1 en. HUET2 en. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c CNB en.

Antioxidant inflammation modulators: C homologated oleanolic acid derivatives. AUC1 en. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring.

JPB2 en. Pyrazoles and pyrimidine tricyclene ketone as antioxidation inflammation regulator. WOA1 en. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof. KRB1 en. CAlkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof.

Devices and methods for supporting and containing premature babies and small-for-age infants. Societe D'etudes Scientifiques Et Industrielles.

Pharmaceutical composition comprising erythromycin and metoclopramide and method of preparing same. Use of macrolide compounds for the treatment of reversible obstructive airways disease. USA en. Sigma-Tau Industrie Farmaceutiche Riunite S. Pharmaceutical composition comprising L-carnitine or derivative thereof and trihydroxy or tetrahydroxystilbene.

Administration of resveratrol to prevent or treat restenosis following coronary intervention. Treating inflammatory diseases of the head and neck with cyclooxygenase-2 inhibitors. Method and composition for prophylaxis and treatment of symptoms associated with cold and influenza-like illnesses.

EPA2 en. Development Biotechnological Processes di Rossi Valentina e C. Children's Hospital Oakland Research Institute. Anderson et al. Ashby et al. Barner et al. Blackwell et al. Bowers et al. Cazzola et al. Damianaki et al. Dweik et al. ElAttar et al. Frankel et al. Fröde-Saleh et al. Gerhäuser et al.

Food Chem. Goodwin , " Immunologic Effects of Nonsteroidal Anti-Inflammatory Drugs, " Am. Guo et al. Health Perspect. Jayatilake et al. Jeandet et al. Kawanda et al. Koh et al. Kulmacz et al. Kakunaga et al. Press, Toronto, pp.

Lee et al. Manna et al. Mannila et al. Martinez et al. Misko et al. Miura et al. Mondal et al. Moon et al. Dawson et al. Quim Newton et al. Pace-Asciak et al. Pang et al. Prochaska et al. Reznikoff et al.

Sanders et al. Sharkey et al. Care Med. Sharma et al. Sharmon et al. Slowing et al. of Ethnopharmacol. Soleas et al. Sporn et al. Subbaramaiah et al. Suh et al. Tardif et al. Medicine 6 Tsuruga et al. van der Ouderaa et al. Wadsworth et al. Wattenberg , " Prevention-Therapy-Basic Science and the Resolution of the Cancer Problem: Presidential Address, " Cancer Research Wild et al.

Zhang et al. Methods for making pharmaceutical formulations comprising microparticles with improved dispersibility, suspendability or wettability. Clarithromycin or salt thereof for use in the treatment or prevention of pulmonary disease induced by destruction of pulmonary alveoli.

Prolyl endopeptidase inhibitors for reducing or preventing neutrophilic inflammation.

Resveratrol and respiratory health heapth disease Digestive health and diarrhea is a heterogeneous group of diseases characterized Resveratrkl lung injury caused by Rseveratrol fibroblast proliferation, interstitial inflammation, and Resveratrol and respiratory health. Resveratrll cell signal transduction pathways are activated in response to helath proinflammatory or Redveratrol cytokines, rexpiratory as IL-6, and these cytokines are increased in different ILDs. This finding suggests the importance of signal transduction pathways in patients with ILD. In this review, advances in lung protection and the underlying mechanisms of RSV are summarized, and the potential efficacy of RSV as a promising treatment option for ILD is highlighted. Interstitial lung disease ILD includes a group of heterogeneous diseases, which can be derived from a variety of different etiology, such as infection, drug, radiation-induced lung diseases and autoimmune diseases such as rheumatoid arthritis RAetc. ILD was characterized by inflammation or fibrosis of different degrees in the lung parenchyma.